Discovering and developing new drugs need high expenditure and prolonged timeline, which are major roadblocks for creating therapies for infectious diseases. To discover economically friendly new treatments against various diseases, Creative Biolabs takes a repurposing approach from existing drugs for drug discovery.
With the rise of antibiotic-resistant bacteria especially the appearance of superbugs owing multidrug resistant ability, the World Health Organization (WHO) suggests us to enter a “post-antibiotic era” in this century. However, current antibiotics discovery does not work very efficiently, and new drugs need long time scope for administration. Finding new uses for existing drugs provides a convenient and effective way for antibacterial drug discovery. Some antibacterial properties have been discovered in existing anticancer, antifungal, anthelmintic, and anti-inflammatory drugs. Creative Biolabs deploys different strategies to identify previously drugs with antibacterial activity.
Drug repurposing (also referred to as drug repositioning) refers to the identification of new indications from existing drugs, or the application of newly identified drugs to the treatment of diseases other than the drug's intended disease. Comparing with traditional step-by-step drug discovery, drug repurposing has several advantages, including saving the overall expenditure and time, compounds having known pharmacological properties and low toxicity.
Creative Biolabs provides several tools for antibacterial drug repurposing.
Virtual Discovery Using Analysis Tools
Computer-aided drug discovery is a powerful tool in identifying reposition drugs from known drug data. As years of accumulation of structure and pharmaceutical information of and therapeutic active compounds and proteins, Creative Biolabs can utilize online public databases and bioinformatics tools to identify interaction networks between drugs and targets. We have experienced scientists in bioinformatics and computational science, who can analyze the target-compound interactions to meet all your demands. Our in silico drug repositioning platform represents an alternative and complementary approach for activity-based drug discovery.
Favored Target Screening the Pharmacopeia against New Targets
Creative Biolabs takes advantage of several target-based and cell-based techniques to rescreen known drugs against an array of previously inaccessible disease-relevant targets. By this approach, we can identify new therapeutic agents for validated targets and an unexpected new use for existing drugs.
End-Point Screening to Discover New Uses for Both Off- and On-Target Effects of Existing Drug
End-point screening may have significant therapeutic impact to discover both on- and off-target effects of compounds. This approach has the potential to identify both "known compound-new target" and "known target-new indication" classes of repurposed drugs. Once identified, these drugs can rapidly be introduced into clinical testing to validate the screening hit.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
For Research Use Only.
